Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.47 |
| ▸ | HTR2A | P28223 | 13/20 | 0.47 |
| ▸ | HTR2B | P41595 | 12/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | WEE1 | P30291 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890371 | 1.00 | HTR2C (0.47) | HTR2CHTR2AHTR2BADRB1DRD2 | |
| SCHEMBL5632098 | 1.00 | HTR2C (0.47) | HTR2CHTR2AHTR2BADRB1DRD2 | |
| Hydrochloric Acid SCHEMBL5632410 | 0.99 | HTR2C (0.49) | HTR2CHTR2AHTR2BADRB1DRD2 | |
| Hydrochloric Acid SCHEMBL5632420 | 0.99 | HTR2C (0.49) | HTR2CHTR2AHTR2BADRB1DRD2 | |
| Hydrochloric Acid SCHEMBL5632808 | 0.99 | HTR2C (0.49) | HTR2CHTR2AHTR2BADRB1DRD2 | |
| SCHEMBL5631556 | 0.85 | DRD2 (0.55) | HTR2CHTR2AHTR2BADRB1DRD2 | |
| SCHEMBL30066000 | 0.85 | DRD2 (0.55) | HTR2CHTR2AHTR2BADRB1DRD2 | |
| SCHEMBL14442452 | 0.85 | HTR2C (0.46) | HTR2CHTR2AHTR2B | |
| SCHEMBL14442453 | 0.85 | HTR2C (0.46) | HTR2CHTR2AHTR2B | |
| SCHEMBL5631562 | 0.85 | DRD2 (0.55) | HTR2CHTR2AHTR2BADRB1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| CN-1809545-A | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c | ARENA PHARM INC (US) | 2006-07-26 | — | — | CN | claimed |
| EP-1644347-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005016902-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20210052600-A1 | THERAPEUTIC AGENTS FOR STRESS URINARY INCONTINENCE AND INCOTINENCE OF FECES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3733204-A1 | THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20080255137-A1 | N-Biaryl and N-Arylheteroaryl 2-Substituted Piperazine Derivatives as Modulators of the 5ht2c Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| CN-101084206-A | N-biaryl and n-arylheteroaryl 2-substituted piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto | ARENA PHARM INC (US) | 2007-12-05 | — | — | CN | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| CN-1809545-A | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c | ARENA PHARM INC (US) | 2006-07-26 | — | — | CN | disclosed |
| EP-1644347-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005016902-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255137-A1 | N-Biaryl and N-Arylheteroaryl 2-Substituted Piperazine Derivatives as Modulators of the 5ht2c Receptor Useful for the Treatment of Disorders Related Thereto | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2A 2/4885HTR2B 5/4885 |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2A 2/4885HTR2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.